🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. 400 microgrammes GSK961081

    Theravance Biopharma Ireland Umited

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  2. 400 µg of MBX 2109 once-weekly by subcutaneous injection

    MBX Biosciences

    Hypoparathyroidism

    phase 2 small molecule active

    1 trial

  3. 413ABM

    BRIGHT MINDS BIOSCIENCES INC.

    MALARIA

    phase 2 other completed

    1 trial

  4. 4D-125 IVT Injection

    4D Molecular Therapeutics

    X-Linked Retinitis Pigmentosa

    phase 2 mab active

    1 trial

  5. 4D-150 IVT

    4D Molecular Therapeutics

    Neovascular (Wet) Age-Related Macular Degeneration

    phase 2 mab active

    1 trial

  6. 4D-150 IVT

    4D Molecular Therapeutics

    Diabetic Macular Edema

    phase 2 mab active

    1 trial

  7. 4D-310

    4D Molecular Therapeutics

    Fabry Disease

    phase 2 mab active

    2 trials

  8. 4D-710

    4D Molecular Therapeutics

    Cystic Fibrosis Lung

    phase 2 mab active

    1 trial

  9. 5 mg/kg CM-101

    Chemomab Therapeutics

    Nonalcoholic Steatohepatitis

    phase 2 mab completed

    1 trial

  10. 5-(1-(2-[18F] fluoroethoxy))-[3-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-propyl]-5,6,7,8-tetrahydronaphthalen

    Disc Medicine

    Alzheimers Disease, sporadic Cerebral Amyloid Angiopathy, Parkinson

    phase 2 small molecule active

    1 trial

  11. 5-FU medac 50 mg/ml, Injektionslösung, ELVN-002, BENDAFOLIN 10 mg/ml Injektionslösung, ELVN-002, ELVN-002, ELVN-002, ELVN-002, Benda-5 FU 50 mg/ml Injektionslösung, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, ELVN-002, Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, HALAVEN 0.44 mg/ml solution for injection, Capecitabin "Zentiva", filmovertrukne tabletter, ELVN-002, Herceptin 150 mg powder for concentrate for solution for infusion, Capecitabine Ac

    Enliven Therapeutics

    Solid Tumors, Colorectal Cancer and Breast Cancer

    phase 2 small molecule active

    1 trial

  12. 514G3 (2 mg/kg) plus standard IV antibiotic treatment

    XBiotech Germany GmbH

    Staphylococcus Aureus Bacteremia

    phase 2 mab completed

    1 trial

  13. 5μg/ml ESAT6-CFP10

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Tuberculosis

    phase 2 mab completed

    1 trial

  14. 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Tuberculosis

    phase 2 mab completed

    1 trial

  15. 60 mg PRAX-114 or 40 mg PRAX-114

    Chongqing Precision Biotech Co., Ltd

    Post-traumatic Stress Disorder

    phase 2 small molecule terminated

    1 trial

  16. 601

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Pathological Myopic Choroidal Neovascularization

    phase 2 small molecule active

    1 trial

  17. 601 1.25mg

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Central Retinal Vein Occlusion

    phase 2 small molecule completed

    1 trial

  18. 610 100mg

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Asthma

    phase 2 small molecule active

    1 trial

  19. 611 150mg

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Dermatitis, Atopic

    phase 2 small molecule completed

    1 trial

  20. 611 300 mg Q2W

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  21. 611 Q2W

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Dermatitis, Atopic

    phase 2 small molecule completed

    1 trial

  22. 68GA-FAPI-46

    Disc Medicine

    Graves' Orbitopathy

    phase 2 small molecule active

    1 trial

  23. 68Ga-Dotatoc

    Disc Medicine

    nasopharyngeal carcinoma

    phase 2 small molecule active

    1 trial

  24. 68Ga-FAPI-46

    The George Institute

    Non-metastatic Pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources